Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2019

30.07.2019 | short review

ASH 2018—aggressive lymphoma

verfasst von: Dr. Michael Panny

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

At the American Society of Hematology Meeting (ASH) 2018 promising data were presented reflecting the impressing advances of clinical research in aggressive lymphoma. Besides promising and partially practice-changing therapies in first-line treatment, there was a focus on Chimeric Antigen Receptor T Cell (CART) therapy for patients with relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL): longer follow-up, real world data and new developments were reported. A bit overshadowed by CART therapy hype promising data for adding venetoclax to chemoimmuntherapy, bispecific antibodies, antibody drug conjugates and new monoclonal antibodies were presented. Important data to detect patients at high risk for R/CHOP (Rituximab/Cyclophospamide, Doxorubicin, Vincristine, Prednisone) failure and to detect possible targets for this high-risk subgroup were shown. The focus of phase III studies in the future should be on this high-risk population as the next phase III trial—the PHOENIX study adding ibrutinib to R/CHOP in non GCB DLBCL—failed to improve standard first-line therapy with R/CHOP.
Literatur
1.
Zurück zum Zitat Rosenwald A, et al. Prognostic Significance of MYC Single, Double, Triple Hit and MYC-Translocation Partner Status in Diffuse Large B‑Cell Lymphoma—a Study By the Lunenburg Lymphoma Biomarker Consortium (LLBC). Blood. 2018;132:344. Rosenwald A, et al. Prognostic Significance of MYC Single, Double, Triple Hit and MYC-Translocation Partner Status in Diffuse Large B‑Cell Lymphoma—a Study By the Lunenburg Lymphoma Biomarker Consortium (LLBC). Blood. 2018;132:344.
2.
Zurück zum Zitat Staiger AM, et al. A new Stromal signature applicable to formalin-fixed paraffin-embedded tissues identifies patients at risk in prospective clinical trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2018;132:343. CrossRef Staiger AM, et al. A new Stromal signature applicable to formalin-fixed paraffin-embedded tissues identifies patients at risk in prospective clinical trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2018;132:343. CrossRef
3.
Zurück zum Zitat Poeschel V, et al. Excellent outcome of young patients (18–60 years) with favourable-prognosis diffuse large B‑cell Lymphoma (DLBCL) treated with 4 cycles CHOP plus 6 applications of Rituximab: results of the 592 patients of the flyer trial of the Dshnhl/GLA. Blood. 2018;132:781. Poeschel V, et al. Excellent outcome of young patients (18–60 years) with favourable-prognosis diffuse large B‑cell Lymphoma (DLBCL) treated with 4 cycles CHOP plus 6 applications of Rituximab: results of the 592 patients of the flyer trial of the Dshnhl/GLA. Blood. 2018;132:781.
4.
Zurück zum Zitat Younes A, et al. A global, randomized, placebo-controlled, phase 3 study of Ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) in patients with previously untreated non-germinal center B‑cell-like (GCB) diffuse large B‑cell Lymphoma (DLBCL). Blood. 2018;132:784. Younes A, et al. A global, randomized, placebo-controlled, phase 3 study of Ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) in patients with previously untreated non-germinal center B‑cell-like (GCB) diffuse large B‑cell Lymphoma (DLBCL). Blood. 2018;132:784.
5.
Zurück zum Zitat Davies A, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B‑cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(5):P649–P62. CrossRef Davies A, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B‑cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(5):P649–P62. CrossRef
6.
Zurück zum Zitat Leonard JP, et al. Randomized phase II study of R‑CHOP with or without Bortezomib in previously untreated patients with non-germinal center B‑cell-like diffuse large B‑cell Lymphoma. J Clin Oncol. 2017;35(31):3538–46. CrossRef Leonard JP, et al. Randomized phase II study of R‑CHOP with or without Bortezomib in previously untreated patients with non-germinal center B‑cell-like diffuse large B‑cell Lymphoma. J Clin Oncol. 2017;35(31):3538–46. CrossRef
7.
Zurück zum Zitat Vitolo U, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B‑cell lymphoma. J Clin Oncol. 2017;35(31):3529–37. CrossRef Vitolo U, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B‑cell lymphoma. J Clin Oncol. 2017;35(31):3529–37. CrossRef
8.
Zurück zum Zitat Witzig TE, et al. Adjuvant everolimus in high-risk diffuse large B‑cell lymphoma: final results from the PILLAR-2 randomized phase III trial. Ann Oncol. 2018;29(3):707–14. CrossRef Witzig TE, et al. Adjuvant everolimus in high-risk diffuse large B‑cell lymphoma: final results from the PILLAR-2 randomized phase III trial. Ann Oncol. 2018;29(3):707–14. CrossRef
9.
Zurück zum Zitat Crump M, et al. Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B‑cell Lymphoma. J Clin Oncol. 2016;34(21):2484–92. CrossRef Crump M, et al. Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B‑cell Lymphoma. J Clin Oncol. 2016;34(21):2484–92. CrossRef
10.
Zurück zum Zitat Franck Morschhauser, et al. Venetoclax plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) improves outcomes in BCL2-positive first-line diffuse large B‑cell Lymphoma (DLBCL): first safety, efficacy and Biomarker analyses from the phase II CAVALLI study. Blood. 2018;132:782. Franck Morschhauser, et al. Venetoclax plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) improves outcomes in BCL2-positive first-line diffuse large B‑cell Lymphoma (DLBCL): first safety, efficacy and Biomarker analyses from the phase II CAVALLI study. Blood. 2018;132:782.
11.
Zurück zum Zitat Chamuleau MED, et al. Successful treatment of MYC rearrangement positive large B cell lymphoma patients with R‑CHOP21 plus lenalidomide: results of a multicenter phase II HOVON trial. Blood. 2018;132:786. Chamuleau MED, et al. Successful treatment of MYC rearrangement positive large B cell lymphoma patients with R‑CHOP21 plus lenalidomide: results of a multicenter phase II HOVON trial. Blood. 2018;132:786.
12.
Zurück zum Zitat Locke FL, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B‑cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42. CrossRef Locke FL, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B‑cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42. CrossRef
13.
Zurück zum Zitat Nastoupil LJ, et al. Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T‑cell therapy for relapsed/refractory large B‑cell lymphoma: real world experience. Blood. 2018;132:91. CrossRef Nastoupil LJ, et al. Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T‑cell therapy for relapsed/refractory large B‑cell lymphoma: real world experience. Blood. 2018;132:91. CrossRef
14.
Zurück zum Zitat Neelapu SS, et al. 2‑year follow-up and high-risk subset analysis of zuma-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients with refractory large B cell lymphoma. Blood. 2018;132:2967. Neelapu SS, et al. 2‑year follow-up and high-risk subset analysis of zuma-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients with refractory large B cell lymphoma. Blood. 2018;132:2967.
15.
Zurück zum Zitat Lung-Ji Chang, et al. Phase I/II trial of multi-target chimeric antigen receptor modified T cells (4SCAR2.0) against relapsed or refractory lymphomas. Blood. 2018;132:225. Lung-Ji Chang, et al. Phase I/II trial of multi-target chimeric antigen receptor modified T cells (4SCAR2.0) against relapsed or refractory lymphomas. Blood. 2018;132:225.
16.
Zurück zum Zitat Park JH, et al. A phase I first-in-human clinical trial of CD19-targeted 19-28z/4-1BBL “armored” CAR T cells in patients with relapsed or refractory NHL and CLL including richter’s transformation. Blood. 2018;132:224. Park JH, et al. A phase I first-in-human clinical trial of CD19-targeted 19-28z/4-1BBL “armored” CAR T cells in patients with relapsed or refractory NHL and CLL including richter’s transformation. Blood. 2018;132:224.
17.
Zurück zum Zitat Henia Dar, et al. Preclinical development of CTX120, an allogeneic CAR-T cell targeting Bcma. Blood. 2018;132:1921. Henia Dar, et al. Preclinical development of CTX120, an allogeneic CAR-T cell targeting Bcma. Blood. 2018;132:1921.
18.
Zurück zum Zitat Chong EA, et al. Sequential anti-CD19 directed chimeric antigen receptor modified T‑cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or refractory B‑cell non-Hodgkin lymphomas. Blood. 2018;132:4198. Chong EA, et al. Sequential anti-CD19 directed chimeric antigen receptor modified T‑cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or refractory B‑cell non-Hodgkin lymphomas. Blood. 2018;132:4198.
19.
Zurück zum Zitat Hirayama AV, et al. Efficacy and toxicity of JCAR014 in combination with durvalumab for the treatment of patients with relapsed/refractory aggressive B‑cell non-hodgkin Lymphoma. Blood. 2018;132:1680. Hirayama AV, et al. Efficacy and toxicity of JCAR014 in combination with durvalumab for the treatment of patients with relapsed/refractory aggressive B‑cell non-hodgkin Lymphoma. Blood. 2018;132:1680.
20.
Zurück zum Zitat Salles GA, et al. Single-arm phase II study of MOR208 combined with Lenalidomide in patients with relapsed or refractory diffuse large B‑cell lymphoma: L‑mind. Blood. 2018;132:227. Salles GA, et al. Single-arm phase II study of MOR208 combined with Lenalidomide in patients with relapsed or refractory diffuse large B‑cell lymphoma: L‑mind. Blood. 2018;132:227.
21.
Zurück zum Zitat Caimi P, et al. Safety and efficacy of Venetoclax combined with rituximab, Ifosfamide, carboplatin and etoposide chemoimmunotherapy (VICER) for treatment of relapsed diffuse large B cell Lymphoma: results from the phase 1 study. Blood. 2018;132:397. Caimi P, et al. Safety and efficacy of Venetoclax combined with rituximab, Ifosfamide, carboplatin and etoposide chemoimmunotherapy (VICER) for treatment of relapsed diffuse large B cell Lymphoma: results from the phase 1 study. Blood. 2018;132:397.
22.
Zurück zum Zitat Sehn LH, et al. Polatuzumab Vedotin (Pola) plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in relapsed/refractory (R/R) diffuse large B‑cell Lymphoma (DLBCL): updated results of a phase (Ph) Ib/II study. Blood. 2018;132:1683. Sehn LH, et al. Polatuzumab Vedotin (Pola) plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in relapsed/refractory (R/R) diffuse large B‑cell Lymphoma (DLBCL): updated results of a phase (Ph) Ib/II study. Blood. 2018;132:1683.
23.
Zurück zum Zitat Budde LE, et al. Mosunetuzumab, a full-length bispecific CD20/CD3 antibody, displays clinical activity in relapsed/refractory B‑cell non-Hodgkin lymphoma (NHL): interim safety and efficacy results from a phase 1 study. Blood. 2018;132:399. Budde LE, et al. Mosunetuzumab, a full-length bispecific CD20/CD3 antibody, displays clinical activity in relapsed/refractory B‑cell non-Hodgkin lymphoma (NHL): interim safety and efficacy results from a phase 1 study. Blood. 2018;132:399.
24.
Zurück zum Zitat Hutchings M, et al. CD20-Tcb (RG6026), a novel “2:1” format T‑cell-engaging Bispecific antibody, induces complete remissions in relapsed/refractory B‑cell non-hodgkin’s lymphoma: preliminary results from a phase I first in human trial. Blood. 2018;132:226. CrossRef Hutchings M, et al. CD20-Tcb (RG6026), a novel “2:1” format T‑cell-engaging Bispecific antibody, induces complete remissions in relapsed/refractory B‑cell non-hodgkin’s lymphoma: preliminary results from a phase I first in human trial. Blood. 2018;132:226. CrossRef
Metadaten
Titel
ASH 2018—aggressive lymphoma
verfasst von
Dr. Michael Panny
Publikationsdatum
30.07.2019
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-019-0510-9